Prokarium Ltd is a clinical stage SME with a dual business model: Development of in-house oral vaccines and out-licensing of its Vaxonella oral vaccine delivery platform. Currently the focus is on a dual diarrhoea and typhoid vaccine as well as a Clostridium difficile vaccine. Prokarium has raised Series A financing from Flerie Invest AB, completed GMP manufacture and toxicology studies and is now progressing to its first clinical trial on Typhetec with results expected Dec 2015. Prokarium is interested in meeting with investors for a £12/$20 million Series B financing to close early 2016.

If you are interested to know more about investing in Prokarium, please take a look at the following presentation and/or contact us to receive more detailed information:

Prokarium Investor Presentation 15 Jan 2015

Partnering with organisations interested in using the Vaxonella® platform is also a priority for Prokarium. If you have a vaccine candidate that you want to evaluate in an oral vaccine delivery platform, with the advantages of a single manufacturing platform, strong mucosal immune response and ease of manufacture, then we can offer to clone your antigens into our platform for you to evaluate in your established preclinical models. For more details on the advantages of oral delivery using Vaxonella, see the Technology section.